The Targeted Agent and Profiling Utilization Registration (TAPUR) study


The TAPUR study is a clinical trial that aims to improve our understanding of how commercially available anti-cancer drugs perform on a broader range of cancers, by matching the drugs to tumors with specific genomic mutations that the drugs are designed to target.


Accepting new patients

Primary Study Objective(s)

  • To describe the anti-tumor activity and toxicity of commercially available, targeted anti-cancer drugs used for treatment of participants with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known to be a drug target or to predict sensitivity to a drug.
  • To record the treatment-related adverse events experienced by participants.
  • To create a prospective database of patient outcomes following treatment of participants with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma that harbors a genomic variant known to be a target of an approved targeted anti-cancer drugs or to predict sensitivity to a drug with a commercially available targeted agent provided by the study.
  • To catalogue the commercially available tumor genomic tests used by clinical oncologists in the usual care of patients with advanced cancer.
  • To determine the concordance of the treatment plan proposed by the treating oncologist with that recommended by the Molecular Tumor Board in applicable situations.

Core eligibility

Note: This is only a partial list of eligibility criteria.

Generally speaking, qualifying participants must:

  • Be 18 or older
  • Not be pregnant or planning to become pregnant during the trial timeline
  • Not be bed-ridden
  • Have been diagnosed with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma
  • Have exhausted available standard treatment options
  • Have had a genomic or molecular test performed on their tumor
  • Have genomic test results that reveal their tumor has a mutation that may be targeted with a drug included in the trial and not approved for that cancer type
Learn more about your cancer